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Abstract 
Review on t(1;1)(q24;q25)/inv(1)(q24q25), with 
data on clinics, and the genes involved 
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Clinics and pathology 
Disease 
B-lymphoblastic leukemia, BCR-ABL1-like 
(WHO, 2016). 
Epidemiology 
Only 2 cases described: a 20-years-old man 
(Roberts et al, 2014; Raca et al., 2015; Roberts et 
al., 2017) and a second patient without further data 
(case A530 in Boer et al., 2017). These cases were 
first classified as B-ALL, and reclassified later as 
"B-ALL, BCR-ABL1-like" after characterization 
[CHU1]of the RCSD1/ABL2 fusion.  
The RCSD1/ABL2 case described by Roberts et al, 
2014 was part of a study of 1665 B-ALL cases, 
three of which with ABL2 fusions. In the case 
described in Boer et al., 2017, the RCDS1/ABL2 
fusion case was identified in a series of 77 BCR-
ABL1-like B-ALL cases. 
Treatment 
The 20-year-old case received induction therapy 
with vincristine/peg-
asparaginase/daunorubicin/prednisone with 
intrathecal cytorabine and methotrexate; there was 
no response post induction at days 15 and 29). 
Additional therapy included Cytoxan, cytarabine, 6-
mercaptopurine, decadron, vincristine, peg-
asparaginase and intrathecal therapy with 
methotrexate (8-week cycle) and produced a 
morphologic remission but high-level minimal 
residual disease (MRD) was detected by flow 
cytometry.  
The patient received a hematopoietic stem cell 
transplant (total body irradiation and etoposide 
based preparative regimen) from an unrelated donor 
(Raca et al., 2015). The other case was treated 
according to the ALL10-HR protocol. There was a 
good response to prednisone, and high MRD (Boer 
et al., 2017). 
Evolution 
The 20-year-old case was in complete remission 8 
month post-transplant and with no evidence of 
MRD (Raca et al., 2015). The other patient has 
been followed up for 3-4 years (Boer et al., 2017). 
Prognosis 
The two cases showed a IKZF1 deletion. Roberts et 
al. showed a tyrosine kinase inhibitors sensitivity 
when the RCSD1/ABL2 fusion was tested in Ba/F3 
cells and in vivo mice models, and dasatinib was 
proposed to be evaluated in the future treatment of 
BCR-ABL1-like B-ALL with ABL-class fusions, 




This abnormality was not detected by conventional 
cytogenetic in any of the two cases. A complex 
rearrangement necessarily occurs because the two 
genes are in opposite directions of transcription. 
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Cytogenetics molecular 
The rearrangement can be detected by molecular 
cytogenetics or other molecular technics. 





416 amino acids. RCSD1 is also called CAPZIP. 
CapZ-interacting protein, implication in 
cytoskeleton regulation and cell migration. RCSD1 
is a mediator of non-canonical Wnt/JNK signalling. 
It interacts with the actin capping protein CapZ 
(CAPZA1, CAPZA2, CAPZB: capping actin 
protein of muscle Z-line subunits alpha 1, alpha 2 
and beta). RCSD1 Binds CapZ to prevent CapZ 
from binding to the actin cytoskeleton. The T-cell 
costimulatory receptor CD28 phosphorylation 





1182 amino acids. ABL2 is also called ARG. ABL2 
is a member of the ABL family of tyrosine kinases. 
ABL kinases have been found to play essential 
roles for the downstream signaling of the T- and B-
cell receptors. ABL1 and ABL2 have both 
overlapping and distinct functions. The two 
proteins diverge in their C-terminal halves: ABL2 
contains two F-actin binding domains and a 
microtubule-binding domain and is a key regulator 
of actin cytoskeletal remodeling. ABL2 acts as 
negative regulator of signaling downstream of the 
kinase activity of the transmembrane receptor 
protein tyrosine kinase FLT3: it partially blocks 
FLT3-induced AKT phosphorylation (Jacobsen et 
al., 2018; Kazi et al., 2017). ABL2 gene is often 
implicated in solid tumors. 




5'RCSD1 (exon 3) - 3'ABL2 (exon 5). 
 
 
Figure 1. RCSD1/ABL2 fusion protein, according to https://pecan.stjude.cloud/proteinpaint/ABL2 










The transcript retains the tyrosine kinase domain of 
ABL2 and a portion of the SH2 domain, but not the 
NH2-terminal SH3 domain (Raca et al., 2015). 
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